NM_001412.4:c.17G>T (p.Gly6Val) is a missense variant in the N-terminal tail (NTT) of EIF1AX, a critical functional domain involved in ribosomal scanning, AUG selection, and ribosomal protein binding.¹ This variant is absent from all population databases including gnomAD v2.1, v4.1, and gnomAD-Canada, indicating it is a rare variant not observed in large control populations.² Residue Gly6 lies within a statistically significant mutational hotspot (cancerhotspots.org) and within the NTT functional domain, where recurrent missense mutations are documented in uveal melanoma. Functional studies of the G6D substitution at the same residue demonstrate altered translational regulation and reduced Rps10 binding.³ Multiple in silico tools predict no significant deleterious impact: BayesDel score is -0.263 (benign-leaning) and SpliceAI predicts no splicing alteration (max delta score = 0.00).⁴ This variant has been reported in ClinVar as Uncertain significance by a single clinical laboratory (ClinVar ID: 1708311). It has been observed in somatic cancers (COSMIC; n=2) but no germline clinical or functional evidence specific to this variant is available.⁵ No functional studies have directly tested the G6V substitution. Available functional data for other NTT mutants (G6D, G8R/G9R, K10E, R13H, G15D) demonstrate a gain-of-function mechanism with altered translational control, but these studies do not constitute variant-specific evidence for G6V.⁶ No de novo, segregation, or case-control data are available for this variant.